X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-01-13 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | CFO, Secretary | S - Sale | $9.10 | -10,757 | 226,097 | -5% | -$97,864 | ||||||
2025-01-13 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO | S - Sale | $9.06 | -18,333 | 877,608 | -2% | -$166,082 | ||||||
| D | 2025-01-14 | MRSN | Mersana Therapeutics, Inc. | Protopapas Anna | Dir | S - Sale+OE | $0.66 | -11,534 | 457,376 | -2% | -$7,612 | |||||
| D | 2025-01-14 | MRSN | Mersana Therapeutics, Inc. | Mandelia Ashish | VP, Chief Accounting Officer | S - Sale+OE | $0.66 | -1,007 | 49,396 | -2% | -$665 | |||||
| D | 2025-01-14 | MRSN | Mersana Therapeutics, Inc. | Lowinger Timothy B | SVP, Chief Sci., Tech. Officer | S - Sale+OE | $0.66 | -3,483 | 242,932 | -1% | -$2,299 | |||||
| D | 2025-01-14 | MRSN | Mersana Therapeutics, Inc. | Deschuytner Brian | SVP, COO, CFO | S - Sale+OE | $0.66 | -3,713 | 105,111 | -3% | -$2,451 | |||||
| D | 2025-01-14 | MRSN | Mersana Therapeutics, Inc. | Carvajal Alejandra | SVP, GC | S - Sale+OE | $0.66 | -3,330 | 69,344 | -5% | -$2,198 | |||||
| D | 2025-01-14 | MRSN | Mersana Therapeutics, Inc. | Bala Mohan | SVP, Chief Development Officer | S - Sale+OE | $0.66 | -3,253 | 60,228 | -5% | -$2,147 | |||||
| M | 2025-01-13 | ZYME | Zymeworks Inc. | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $13.59 | +167,654 | 15,578,732 | +1% | +$2,278,811 | |||||
| D | 2025-01-13 | BPMC | Blueprint Medicines Corp | Albers Jeffrey W. | Dir | S - Sale+OE | $102.28 | -5,000 | 157,557 | -3% | -$511,400 | |||||
| D | 2025-01-13 | BPMC | Blueprint Medicines Corp | Hurley Ariel | Principal Accounting Officer | S - Sale+OE | $100.00 | -2,250 | 14,967 | -13% | -$225,000 | |||||
2025-01-15 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.48 | +500,000 | 246,732,605 | 0% | +$740,850 | ||||||
| M | 2025-01-13 | RGLS | Regulus Therapeutics Inc. | Aker Christopher Ray | SVP, GC | S - Sale | $1.26 | -43,635 | 49,546 | -47% | -$55,120 | |||||
| M | 2025-01-13 | RGLS | Regulus Therapeutics Inc. | Hagan Joseph P | CEO | S - Sale | $1.26 | -127,054 | 210,808 | -38% | -$160,495 | |||||
| M | 2025-01-13 | RGLS | Regulus Therapeutics Inc. | Calsada Crispina | CFO | S - Sale | $1.26 | -43,804 | 45,478 | -49% | -$55,333 | |||||
2025-01-13 | RGLS | Regulus Therapeutics Inc. | Klassen Preston | Pres, Head of R, D | S - Sale | $1.26 | -31,445 | 36,055 | -47% | -$39,721 | ||||||
| D | 2025-01-13 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $18.24 | -14,000 | 88,975 | -14% | -$255,413 | |||||
2025-01-13 | IMVT | Immunovant, Inc. | Roivant Sciences Ltd. | Dir, 10% | P - Purchase | $20.00 | +16,845,010 | 96,650,341 | +21% | +$336,900,200 | ||||||
| D | 2025-01-13 | HRMY | Harmony Biosciences Holdings, Inc. | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | S - Sale+OE | $37.04 | -7,180 | 0 | -100% | -$265,946 | |||||
| M | 2025-01-13 | RNAC | Cartesian Therapeutics, Inc. | Springer Timothy A | Dir, 10% | P - Purchase | $17.47 | +20,967 | 9,391,955 | 0% | +$366,354 | |||||
2025-01-15 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $2.23 | +43,000 | 559,925 | +8% | +$95,890 | ||||||
2025-01-15 | ANIX | Anixa Biosciences Inc | Catelani Michael | Pres, COO, CFO | P - Purchase | $2.15 | +9,289 | 44,500 | +26% | +$19,971 | ||||||
2025-01-14 | COGT | Cogent Biosciences, Inc. | Pinnow Cole | Chief Commercial Officer | P - Purchase | $7.60 | +43,750 | 45,848 | >999% | +$332,413 | ||||||
| D | 2025-01-10 | CORT | Corcept Therapeutics Inc | Swisher Daniel N Jr | Dir | S - Sale+OE | $50.54 | -2,200 | 0 | -100% | -$111,188 | |||||
| D | 2025-01-14 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale+OE | $11.78 | -16,393 | 587,978 | -3% | -$193,110 | |||||
| D | 2025-01-14 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale+OE | $11.78 | -6,249 | 270,388 | -2% | -$73,613 | |||||
| D | 2025-01-14 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $11.78 | -8,362 | 215,494 | -4% | -$98,504 | |||||
| D | 2025-01-14 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $11.78 | -23,370 | 401,755 | -5% | -$275,299 | |||||
| D | 2025-01-14 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $11.78 | -4,809 | 180,215 | -3% | -$56,650 | |||||
| D | 2025-01-14 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale+OE | $11.78 | -22,343 | 2,607,439 | -1% | -$263,201 | |||||
| D | 2025-01-13 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $364.62 | -10,000 | 2,577 | -80% | -$3,646,223 | |||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale | $28.70 | -4,965 | 187,892 | -3% | -$142,506 | ||||||
2025-01-13 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $5.24 | -8,568 | 347,581 | -2% | -$44,896 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | S - Sale | $28.70 | -2,685 | 90,269 | -3% | -$77,065 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | CFO | S - Sale | $28.70 | -2,170 | 158,496 | -1% | -$62,284 | ||||||
2025-01-13 | AVDL | Avadel Pharmaceuticals Plc | Thornton Peter J. | Dir | P - Purchase | $8.05 | +10,000 | 104,055 | +11% | +$80,450 | ||||||
2025-01-13 | AVDL | Avadel Pharmaceuticals Plc | Ende Eric J | Dir | P - Purchase | $7.84 | +30,000 | 208,900 | +17% | +$235,218 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | S - Sale | $28.70 | -2,632 | 54,156 | -5% | -$75,544 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | S - Sale | $28.70 | -1,599 | 45,099 | -3% | -$45,895 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | CEO | S - Sale | $28.70 | -6,247 | 1,846,837 | 0% | -$179,302 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | S - Sale | $28.70 | -264 | 56,881 | 0% | -$7,577 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | S - Sale | $28.70 | -2,288 | 1,138,195 | 0% | -$65,670 | ||||||
| D | 2025-01-10 | COLL | Collegium Pharmaceutical, Inc | Kuhlmann Shirley R. | EVP, GC | S - Sale+OE | $33.04 | -27,500 | 119,184 | -19% | -$908,628 | |||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Delong Mark Jeffrey | Chief Business, Strat Officer | S - Sale | $28.70 | -1,599 | 58,796 | -3% | -$45,895 | ||||||
2025-01-13 | APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP, Chief Accounting Officer | S - Sale | $28.70 | -783 | 37,358 | -2% | -$22,474 | ||||||
| M | 2025-01-10 | GBIO | Generation Bio Co. | Quinn Anthony G. | Dir | P - Purchase | $0.96 | +210,791 | 299,286 | +238% | +$203,209 | |||||
| M | 2025-01-10 | GYRE | Gyre Therapeutics, Inc. | Ma Songjiang | Pres | S - Sale | $10.02 | -1,113 | 2,915,138 | 0% | -$11,157 | |||||
| D | 2025-01-10 | CDMO | Avid Bioservices, Inc. | Richieri Richard A. | Chief Operations Officer | S - Sale+OE | $12.37 | -2,483 | 58,320 | -4% | -$30,715 | |||||
| D | 2025-01-08 | OLMA | Olema Pharmaceuticals, Inc. | Bain Capital Life Sciences Investors, LLC | 10% | P - Purchase | $5.76 | +300,000 | 4,300,000 | +8% | +$1,727,370 | |||||
2025-01-10 | IBIO | Ibio, Inc. | Duran Felipe | CFO | P - Purchase | $2.72 | +9,191 | 11,139 | +472% | +$25,000 | ||||||
2025-01-10 | IBIO | Ibio, Inc. | Brenner Martin | See Remarks | P - Purchase | $2.72 | +9,191 | 18,316 | +101% | +$25,000 | ||||||
2025-01-10 | IBIO | Ibio, Inc. | Banjak Marc | GC | P - Purchase | $2.72 | +9,191 | 11,066 | +490% | +$25,000 | ||||||
2025-01-10 | IBIO | Ibio, Inc. | Arkowitz David | Dir | P - Purchase | $2.72 | +18,382 | 18,382 | New | +$49,999 | ||||||
2025-01-10 | IBIO | Ibio, Inc. | Clark William D | Dir | P - Purchase | $2.72 | +1,838 | 1,838 | New | +$4,999 | ||||||
2025-01-10 | IBIO | Ibio, Inc. | Parada Antonio Bernardino Guimaraes | Dir | P - Purchase | $2.72 | +183,823 | 183,823 | New | +$499,999 | ||||||
| D | 2025-01-10 | UTHR | United Therapeutics Corp | Patusky Christopher | Dir | S - Sale+OE | $361.61 | -5,000 | 2,000 | -71% | -$1,808,072 | |||||
2025-01-10 | IBIO | Ibio, Inc. | Sender Gary | Dir | P - Purchase | $2.72 | +9,191 | 9,191 | New | +$25,000 | ||||||
2025-01-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $53.92 | -400 | 55,588 | -1% | -$21,568 | ||||||
2025-01-10 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $12.51 | +2,500 | 5,552,502 | 0% | +$31,275 | ||||||
| DM | 2025-01-07 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $64.70 | -11,218 | 101,549 | -10% | -$725,821 | |||||
| DM | 2025-01-07 | INSM | Insmed Inc | Bonstein Sara | CFO | S - Sale+OE | $65.43 | -6,000 | 118,863 | -5% | -$392,602 | |||||
| DM | 2025-01-07 | INSM | Insmed Inc | Schaeffer Orlov S Nicole | Chief People Strategy Officer | S - Sale+OE | $64.74 | -7,862 | 97,955 | -7% | -$508,973 | |||||
| DM | 2025-01-07 | INSM | Insmed Inc | Wise John Drayton | Chief Commercial Officer | S - Sale+OE | $65.95 | -13,587 | 125,562 | -10% | -$896,074 | |||||
| DM | 2025-01-07 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $65.48 | -15,195 | 677,013 | -2% | -$995,012 | |||||
| DM | 2025-01-07 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale+OE | $65.82 | -3,689 | 69,965 | -5% | -$242,816 | |||||
| DM | 2025-01-07 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale+OE | $64.78 | -9,228 | 147,539 | -6% | -$597,759 | |||||
| M | 2025-01-08 | ZYME | Zymeworks Inc. | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $13.21 | +225,119 | 15,411,078 | +1% | +$2,974,819 | |||||
2025-01-08 | ETST | Earth Science Tech, Inc. | Cazeau Jeff P. H. | Independent Director | P - Purchase | $0.14 | +72,555 | 318,860 | +29% | +$10,519 | ||||||
| A | 2024-08-27 | ETST | Earth Science Tech, Inc. | Cazeau Jeff P. H. | Independent Director | P - Purchase | $0.22 | +45,409 | 96,014 | +90% | +$9,990 | |||||
| A | 2025-01-07 | ETST | Earth Science Tech, Inc. | Cazeau Jeff P. H. | Independent Director | P - Purchase | $0.12 | +79,200 | 246,305 | +47% | +$9,504 | |||||
| A | 2024-11-01 | ETST | Earth Science Tech, Inc. | Cazeau Jeff P. H. | Independent Director | P - Purchase | $0.14 | +71,091 | 167,105 | +74% | +$9,953 | |||||
| D | 2025-01-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale+OE | $24.18 | -28,367 | 336,644 | -8% | -$685,868 | |||||
| M | 2025-01-07 | PTCT | Ptc Therapeutics, Inc. | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | S - Sale | $44.87 | -2,953 | 64,321 | -4% | -$132,493 | |||||
| M | 2025-01-07 | PTCT | Ptc Therapeutics, Inc. | Pauwels Eric | CEO | S - Sale | $44.86 | -3,735 | 86,805 | -4% | -$167,551 | |||||
| M | 2025-01-07 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $44.90 | -4,544 | 283,830 | -2% | -$204,007 | |||||
| M | 2025-01-07 | PTCT | Ptc Therapeutics, Inc. | Golden Lee Scott | EVP, CHIEF MEDICAL OFFICER | S - Sale | $44.84 | -2,008 | 78,651 | -2% | -$90,036 | |||||
| M | 2025-01-07 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale | $44.87 | -3,541 | 106,848 | -3% | -$158,871 | |||||
| M | 2025-01-07 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale | $44.87 | -2,979 | 109,206 | -3% | -$133,674 | |||||
| D | 2025-01-07 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale+OE | $5.31 | -41,666 | 1,154,916 | -3% | -$221,309 | |||||
2025-01-08 | XOMA | Xoma Royalty Corp | Sitko Bradley | Chief Investment Officer | P - Purchase | $25.64 | +545 | 13,514 | +4% | +$13,975 | ||||||
| D | 2025-01-07 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $49.32 | -2,000 | 116,071 | -2% | -$98,640 | |||||
2025-01-08 | AMRX | Amneal Pharmaceuticals, Inc. | Patel Gautam | Dir | S - Sale | $8.01 | -62,590 | 1,968,886 | -3% | -$501,346 | ||||||
| D | 2025-01-08 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Pres, CEO | S - Sale+OE | $41.74 | -17,500 | 365,633 | -5% | -$730,535 | |||||
| A | 2025-01-03 | GYRE | Gyre Therapeutics, Inc. | Ma Songjiang | Pres | S - Sale | $11.85 | -833 | 2,918,467 | 0% | -$9,871 | |||||
2025-01-07 | JANX | Janux Therapeutics, Inc. | Campbell David Alan | Pres, CEO | S - Sale | $60.00 | -5,000 | 293,054 | -2% | -$300,004 | ||||||
2025-01-06 | AMLX | Amylyx Pharmaceuticals, Inc. | Klee Justin B. | Co-CEO | S - Sale | $4.04 | -7,471 | 3,176,788 | 0% | -$30,202 | ||||||
2025-01-06 | AMLX | Amylyx Pharmaceuticals, Inc. | Cohen Joshua B | Co-CEO | S - Sale | $4.05 | -7,471 | 3,213,098 | 0% | -$30,232 | ||||||
| D | 2025-01-07 | BGNE | Beigene, Ltd. | Wang Xiaodong | Chair, Scientific Advisory Brd | S - Sale+OE | $176.50 | -41,760 | 10,324,993 | 0% | -$7,370,515 | |||||
| D | 2025-01-06 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale+OE | $79.68 | -2,483 | 59,981 | -4% | -$197,854 | |||||
| D | 2025-01-06 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $79.68 | -4,016 | 48,034 | -8% | -$320,009 | |||||
| D | 2025-01-06 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | GC | S - Sale+OE | $79.68 | -2,964 | 49,086 | -6% | -$236,182 | |||||
| D | 2025-01-06 | NUVL | Nuvalent, Inc. | Turner Christopher Durant | Chief Medical Officer | S - Sale+OE | $79.68 | -4,016 | 62,547 | -6% | -$320,009 | |||||
| D | 2025-01-06 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $79.68 | -4,016 | 61,734 | -6% | -$320,009 | |||||
| D | 2025-01-06 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $79.68 | -17,301 | 249,062 | -6% | -$1,378,604 | |||||
2025-01-07 | MIRM | Mirum Pharmaceuticals, Inc. | Radovich Peter | Pres, COO | S - Sale | $42.82 | -1,998 | 27,015 | -7% | -$85,545 | ||||||
2025-01-07 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale | $42.82 | -7,489 | 327,929 | -2% | -$320,644 | ||||||
| D | 2025-01-07 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale+OE | $42.82 | -750 | 2,926 | -20% | -$32,111 | |||||
| D | 2025-01-06 | ACXP | Acurx Pharmaceuticals, Inc. | Scodari Joseph C | Dir | P - Purchase | $1.02 | +24,631 | 27,708 | +800% | +$25,000 | |||||
| D | 2025-01-06 | ACXP | Acurx Pharmaceuticals, Inc. | Sailer Carl | Dir | P - Purchase | $1.02 | +24,631 | 142,183 | +21% | +$25,000 | |||||
| D | 2025-01-06 | ACXP | Acurx Pharmaceuticals, Inc. | Luci David P | Pres, CEO, 10% | P - Purchase | $1.02 | +49,261 | 1,147,541 | +4% | +$50,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |